Anebulo Pharmaceuticals (ANEB) Share-based Compensation (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Share-based Compensation of $198530.0 for Q4 2025, down 66.91% year-over-year from $600000.0 in Q4 2024, and down 86.76% quarter-over-quarter from $1.5 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Share-based Compensation (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Share-based Compensation for 6 consecutive years, with $198530.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 66.91% year-over-year to $198530.0; the TTM figure through Dec 2025 stood at $1.4 million (up 11.09% YoY), while the FY2025 annual figure was $1.7 million, up 124.01% from the prior year.
- Share-based Compensation eased to $198530.0 in Q4 2025 per ANEB's latest filing, from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.6 million in Q1 2025 and bottomed at $21928.0 in Q2 2021.
- Historically, Share-based Compensation has averaged $331548.8 across 5 years, with a median of $200000.0 in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 934.99% — and 2025, when it slumped 66.91%.
- Anebulo Pharmaceuticals' Share-based Compensation stood at $94282.0 in 2021, then soared by 112.13% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then surged by 200.0% to $600000.0 in 2024, then plunged by 66.91% to $198530.0 in 2025.
- Business Quant data shows ANEB's Share-based Compensation at $198530.0 in Q4 2025, $1.5 million in Q3 2025, and $300000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 198,530.00 |
| Dec 31, 2025 | 198,530.00 |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 158,884.00 |
| Jun 30, 2024 | 158,884.00 |
| Mar 31, 2024 | 200,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |